Thane Wettig

2021

In 2021, Thane Wettig earned a total compensation of $3.2M as Chief Commercial Officer at FibroGen, a 21% decrease compared to previous year.

Compensation breakdown

Non-Equity Incentive Plan$186,533
Option Awards$1,590,542
Salary$510,000
Stock Awards$874,665
Other$12,855
Total$3,174,595

Wettig received $1.6M in option awards, accounting for 50% of the total pay in 2021.

Wettig also received $186.5K in non-equity incentive plan, $510K in salary, $874.7K in stock awards and $12.9K in other compensation.

Rankings

In 2021, Thane Wettig's compensation ranked 4,217th out of 12,415 executives tracked by ExecPay. In other words, Wettig earned more than 66.0% of executives.

ClassificationRankingPercentile
All
4,217
out of 12,415
66th
Division
Manufacturing
1,739
out of 5,505
68th
Major group
Chemicals And Allied Products
725
out of 2,375
70th
Industry group
Drugs
647
out of 2,096
69th
Industry
Pharmaceutical Preparations
457
out of 1,546
70th

Pay ratio

Thane Wettig's Pay$3,174,595
Median Employee's Pay$174,414
Pay Ratio

18

to 1

In 2021, the annual total compensation of Thane Wettig was $3,174,595.

The annual total compensation of the median employee at FibroGen was $174,414.

The ratio of Thane Wettig's pay to the pay of median employee was therefore 18 to one.

Source: SEC filing on April 28, 2022.

Wettig's colleagues

We found six more compensation records of executives who worked with Thane Wettig at FibroGen in 2021.

2021

Enrique Conterno

FibroGen

Chief Executive Officer

2021

Christine Chung

FibroGen

Senior Vice President, China Operations

2021

Mark Eisner

FibroGen

Chief Medical Officer

2021

Pat Cotroneo

FibroGen

Chief Financial Officer

2021

Elias Kouchakji

FibroGen

Senior Vice President, Clinical Development, Drug Safety, and Pharmacovigilance

2021

Juan Graham

FibroGen

Chief Financial Officer

News

In-depth

You may also like